Registration
Faculty
Overview
View Archive

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas and Seagen Inc., and Merck & Co., Inc.

Medical Crossfire®: How Should We Leverage Immunotherapeutic and Targeted Strategies Across Lines of Care in Bladder Cancer?

Medical Crossfire®: How Should We Leverage Immunotherapeutic and Targeted Strategies Across Lines of Care in Bladder Cancer?


October 20, 2021

Live, Interactive Webcast!

7:00 PM – 9:00 PM EDT

Overview

Bladder cancer represents a heterogeneous collection of tumors with varied outcomes and differing standards of care based on the disease subtype. The armamentarium of therapies for the management of bladder cancer is rapidly expanding. Clinical studies are evaluating a wide variety of approaches, including immunotherapy agents, novel targeted therapies, molecular predictors of response to neoadjuvant chemotherapy, genomics, chemoradiation for muscle-invasive bladder cancer, and adjuvant chemotherapy protocols. It is imperative for oncologists to have knowledge of critical factors to consider when making treatment decisions and in-depth information regarding new and emerging agents for the management of bladder cancer.
 
This Medical Crossfire®: How Should We Leverage Immunotherapeutic and Targeted Strategies Across Lines of Care in Bladder Cancer? live webcast CME program will deliver differing and provocative opinions and treatment approaches from 4 experts who are well versed in the treatment of bladder cancer. The program will begin with an overview of biomarker testing and the utility of biomarkers in the treatment decision-making process. This will be followed by several detailed case presentations and panel discussions on controversial issues. The overarching goal of this program is to provide up-to-date information regarding the efficacy and safety of immunotherapies and targeted agents for bladder cancer across the disease spectrum and help clinicians more deeply understand clinical scenarios where individualizing treatment will optimize patient outcomes.

Benefits of Attending

  • Learn about the latest clinical trial data related to current and emerging immunotherapies and targeted agents for the management of bladder cancer
  • Acquire knowledge regarding best practices for incorporating novel therapies for bladder cancer into clinical practice
  • Gain insight about how the experts approach the treatment of patients with bladder cancer through provocative discussions related to clinical scenarios
  • Ask the experts your most pressing questions regarding the care of patients with bladder cancer

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas and Seagen Inc., and Merck & Co., Inc.

Target Audience

This educational program is directed toward oncologists, urologists, and researchers interested in the treatment of bladder cancers. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with bladder cancers will be invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Outline biomarker testing and interpretation to guide treatment options for immunotherapies and targeted agents in bladder cancer
  • Evaluate efficacy and safety data from clinical trials of emerging single-agent and combination therapeutic approaches across lines of care in bladder cancer
  • Integrate biomarker testing and recent evidence on systemic treatment strategies to optimize care for early and advanced bladder cancer along the care continuum
  • Apply monitoring and mitigation strategies for adverse events associated with targeted and immunotherapeutic treatment options in bladder cancer

Chair

Arjun V. Balar, MD
Arjun V. Balar, MD
Associate Professor of Medicine
Director, Genitourinary Medical Oncology Program
Medical Director - Clinical Trials Office
Perlmutter Cancer Center at NYU Langone Health
New York, NY

Registration

2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701

Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
 
Registration Fee - Free


For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.



Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
282930
Filter By